Research ArticleArticle
Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996-2009
Leslie R. Harrold, Craig Salman, Stanford Shoor, Jeffrey R. Curtis, Maryam M. Asgari, Joel M. Gelfand, Jashin J. Wu and Lisa J. Herrinton
The Journal of Rheumatology April 2013, jrheum.120661; DOI: https://doi.org/10.3899/jrheum.120661
Leslie R. Harrold
From the Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic, Worcester, Massachusetts; Division of Research, Kaiser Permanente Northern California, Oakland, California; The Permanente Medical Group, Santa Clara, California; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Dermatology, University of California at San Francisco, San Francisco, California; Departments of Dermatology, Biostatistics, and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Dermatology, Kaiser Permanente Medical Center, Los Angeles, California, USA. Supported by a grant from the National Institute of Allergy and Infectious Disease (1RC1AI086107-01). Dr. Harrold has a consulting role with the Consortium of Rheumatology Researchers of North America (CORRONA) and was supported by K23AR053856 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Herrinton has research contracts with Centocor, Genentech, and Proctor and Gamble; Dr. Asgari with Genentech; and Dr. Wu with Abbott Laboratories, Amgen, and Pfizer. Dr. Gelfand receives grants to the trustees of the University of Pennsylvania from Amgen, Abbott, and Genentech, and has consulting roles with Amgen, Abbott, Centocor, Pfizer, and Merck. Dr. Curtis receives consulting fees/honoraria and research support from Roche/Genentech, UCB/Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, and Abbott and receives salary support from the U.S. National Institutes of Health (AR053351) and Agency for Healthcare Research and Quality (R01 R01HS018517). L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic; C. Salman, BS, Division of Research, Kaiser Permanente Northern California; S. Shoor, MD, The Permanente Medical Group; J.R. Curtis, MD, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.M. Asgari, MD, MPH, Division of Research, Kaiser Permanente Northern California, and Department of Dermatology, University of California at San Francisco; J.M. Gelfand, MD, MSCE, Departments of Dermatology, Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania; J.J. Wu, MD, Department of Dermatology, Kaiser Permanente Medical Center; L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California. Address correspondence to Dr. L.R. Harrold, Department of Medicine, University of Massachusetts Medical School, Biotech 4, Suite 315, 377 Plantation Street, Worcester, MA 01605, USA. E-mail: Leslie.Harrold{at}umassmed.edu Accepted for publication March 4, 2013.
Craig Salman
From the Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic, Worcester, Massachusetts; Division of Research, Kaiser Permanente Northern California, Oakland, California; The Permanente Medical Group, Santa Clara, California; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Dermatology, University of California at San Francisco, San Francisco, California; Departments of Dermatology, Biostatistics, and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Dermatology, Kaiser Permanente Medical Center, Los Angeles, California, USA. Supported by a grant from the National Institute of Allergy and Infectious Disease (1RC1AI086107-01). Dr. Harrold has a consulting role with the Consortium of Rheumatology Researchers of North America (CORRONA) and was supported by K23AR053856 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Herrinton has research contracts with Centocor, Genentech, and Proctor and Gamble; Dr. Asgari with Genentech; and Dr. Wu with Abbott Laboratories, Amgen, and Pfizer. Dr. Gelfand receives grants to the trustees of the University of Pennsylvania from Amgen, Abbott, and Genentech, and has consulting roles with Amgen, Abbott, Centocor, Pfizer, and Merck. Dr. Curtis receives consulting fees/honoraria and research support from Roche/Genentech, UCB/Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, and Abbott and receives salary support from the U.S. National Institutes of Health (AR053351) and Agency for Healthcare Research and Quality (R01 R01HS018517). L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic; C. Salman, BS, Division of Research, Kaiser Permanente Northern California; S. Shoor, MD, The Permanente Medical Group; J.R. Curtis, MD, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.M. Asgari, MD, MPH, Division of Research, Kaiser Permanente Northern California, and Department of Dermatology, University of California at San Francisco; J.M. Gelfand, MD, MSCE, Departments of Dermatology, Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania; J.J. Wu, MD, Department of Dermatology, Kaiser Permanente Medical Center; L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California. Address correspondence to Dr. L.R. Harrold, Department of Medicine, University of Massachusetts Medical School, Biotech 4, Suite 315, 377 Plantation Street, Worcester, MA 01605, USA. E-mail: Leslie.Harrold{at}umassmed.edu Accepted for publication March 4, 2013.
Stanford Shoor
From the Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic, Worcester, Massachusetts; Division of Research, Kaiser Permanente Northern California, Oakland, California; The Permanente Medical Group, Santa Clara, California; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Dermatology, University of California at San Francisco, San Francisco, California; Departments of Dermatology, Biostatistics, and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Dermatology, Kaiser Permanente Medical Center, Los Angeles, California, USA. Supported by a grant from the National Institute of Allergy and Infectious Disease (1RC1AI086107-01). Dr. Harrold has a consulting role with the Consortium of Rheumatology Researchers of North America (CORRONA) and was supported by K23AR053856 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Herrinton has research contracts with Centocor, Genentech, and Proctor and Gamble; Dr. Asgari with Genentech; and Dr. Wu with Abbott Laboratories, Amgen, and Pfizer. Dr. Gelfand receives grants to the trustees of the University of Pennsylvania from Amgen, Abbott, and Genentech, and has consulting roles with Amgen, Abbott, Centocor, Pfizer, and Merck. Dr. Curtis receives consulting fees/honoraria and research support from Roche/Genentech, UCB/Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, and Abbott and receives salary support from the U.S. National Institutes of Health (AR053351) and Agency for Healthcare Research and Quality (R01 R01HS018517). L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic; C. Salman, BS, Division of Research, Kaiser Permanente Northern California; S. Shoor, MD, The Permanente Medical Group; J.R. Curtis, MD, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.M. Asgari, MD, MPH, Division of Research, Kaiser Permanente Northern California, and Department of Dermatology, University of California at San Francisco; J.M. Gelfand, MD, MSCE, Departments of Dermatology, Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania; J.J. Wu, MD, Department of Dermatology, Kaiser Permanente Medical Center; L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California. Address correspondence to Dr. L.R. Harrold, Department of Medicine, University of Massachusetts Medical School, Biotech 4, Suite 315, 377 Plantation Street, Worcester, MA 01605, USA. E-mail: Leslie.Harrold{at}umassmed.edu Accepted for publication March 4, 2013.
Jeffrey R. Curtis
From the Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic, Worcester, Massachusetts; Division of Research, Kaiser Permanente Northern California, Oakland, California; The Permanente Medical Group, Santa Clara, California; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Dermatology, University of California at San Francisco, San Francisco, California; Departments of Dermatology, Biostatistics, and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Dermatology, Kaiser Permanente Medical Center, Los Angeles, California, USA. Supported by a grant from the National Institute of Allergy and Infectious Disease (1RC1AI086107-01). Dr. Harrold has a consulting role with the Consortium of Rheumatology Researchers of North America (CORRONA) and was supported by K23AR053856 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Herrinton has research contracts with Centocor, Genentech, and Proctor and Gamble; Dr. Asgari with Genentech; and Dr. Wu with Abbott Laboratories, Amgen, and Pfizer. Dr. Gelfand receives grants to the trustees of the University of Pennsylvania from Amgen, Abbott, and Genentech, and has consulting roles with Amgen, Abbott, Centocor, Pfizer, and Merck. Dr. Curtis receives consulting fees/honoraria and research support from Roche/Genentech, UCB/Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, and Abbott and receives salary support from the U.S. National Institutes of Health (AR053351) and Agency for Healthcare Research and Quality (R01 R01HS018517). L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic; C. Salman, BS, Division of Research, Kaiser Permanente Northern California; S. Shoor, MD, The Permanente Medical Group; J.R. Curtis, MD, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.M. Asgari, MD, MPH, Division of Research, Kaiser Permanente Northern California, and Department of Dermatology, University of California at San Francisco; J.M. Gelfand, MD, MSCE, Departments of Dermatology, Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania; J.J. Wu, MD, Department of Dermatology, Kaiser Permanente Medical Center; L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California. Address correspondence to Dr. L.R. Harrold, Department of Medicine, University of Massachusetts Medical School, Biotech 4, Suite 315, 377 Plantation Street, Worcester, MA 01605, USA. E-mail: Leslie.Harrold{at}umassmed.edu Accepted for publication March 4, 2013.
Maryam M. Asgari
From the Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic, Worcester, Massachusetts; Division of Research, Kaiser Permanente Northern California, Oakland, California; The Permanente Medical Group, Santa Clara, California; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Dermatology, University of California at San Francisco, San Francisco, California; Departments of Dermatology, Biostatistics, and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Dermatology, Kaiser Permanente Medical Center, Los Angeles, California, USA. Supported by a grant from the National Institute of Allergy and Infectious Disease (1RC1AI086107-01). Dr. Harrold has a consulting role with the Consortium of Rheumatology Researchers of North America (CORRONA) and was supported by K23AR053856 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Herrinton has research contracts with Centocor, Genentech, and Proctor and Gamble; Dr. Asgari with Genentech; and Dr. Wu with Abbott Laboratories, Amgen, and Pfizer. Dr. Gelfand receives grants to the trustees of the University of Pennsylvania from Amgen, Abbott, and Genentech, and has consulting roles with Amgen, Abbott, Centocor, Pfizer, and Merck. Dr. Curtis receives consulting fees/honoraria and research support from Roche/Genentech, UCB/Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, and Abbott and receives salary support from the U.S. National Institutes of Health (AR053351) and Agency for Healthcare Research and Quality (R01 R01HS018517). L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic; C. Salman, BS, Division of Research, Kaiser Permanente Northern California; S. Shoor, MD, The Permanente Medical Group; J.R. Curtis, MD, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.M. Asgari, MD, MPH, Division of Research, Kaiser Permanente Northern California, and Department of Dermatology, University of California at San Francisco; J.M. Gelfand, MD, MSCE, Departments of Dermatology, Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania; J.J. Wu, MD, Department of Dermatology, Kaiser Permanente Medical Center; L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California. Address correspondence to Dr. L.R. Harrold, Department of Medicine, University of Massachusetts Medical School, Biotech 4, Suite 315, 377 Plantation Street, Worcester, MA 01605, USA. E-mail: Leslie.Harrold{at}umassmed.edu Accepted for publication March 4, 2013.
Joel M. Gelfand
From the Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic, Worcester, Massachusetts; Division of Research, Kaiser Permanente Northern California, Oakland, California; The Permanente Medical Group, Santa Clara, California; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Dermatology, University of California at San Francisco, San Francisco, California; Departments of Dermatology, Biostatistics, and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Dermatology, Kaiser Permanente Medical Center, Los Angeles, California, USA. Supported by a grant from the National Institute of Allergy and Infectious Disease (1RC1AI086107-01). Dr. Harrold has a consulting role with the Consortium of Rheumatology Researchers of North America (CORRONA) and was supported by K23AR053856 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Herrinton has research contracts with Centocor, Genentech, and Proctor and Gamble; Dr. Asgari with Genentech; and Dr. Wu with Abbott Laboratories, Amgen, and Pfizer. Dr. Gelfand receives grants to the trustees of the University of Pennsylvania from Amgen, Abbott, and Genentech, and has consulting roles with Amgen, Abbott, Centocor, Pfizer, and Merck. Dr. Curtis receives consulting fees/honoraria and research support from Roche/Genentech, UCB/Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, and Abbott and receives salary support from the U.S. National Institutes of Health (AR053351) and Agency for Healthcare Research and Quality (R01 R01HS018517). L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic; C. Salman, BS, Division of Research, Kaiser Permanente Northern California; S. Shoor, MD, The Permanente Medical Group; J.R. Curtis, MD, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.M. Asgari, MD, MPH, Division of Research, Kaiser Permanente Northern California, and Department of Dermatology, University of California at San Francisco; J.M. Gelfand, MD, MSCE, Departments of Dermatology, Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania; J.J. Wu, MD, Department of Dermatology, Kaiser Permanente Medical Center; L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California. Address correspondence to Dr. L.R. Harrold, Department of Medicine, University of Massachusetts Medical School, Biotech 4, Suite 315, 377 Plantation Street, Worcester, MA 01605, USA. E-mail: Leslie.Harrold{at}umassmed.edu Accepted for publication March 4, 2013.
Jashin J. Wu
From the Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic, Worcester, Massachusetts; Division of Research, Kaiser Permanente Northern California, Oakland, California; The Permanente Medical Group, Santa Clara, California; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Dermatology, University of California at San Francisco, San Francisco, California; Departments of Dermatology, Biostatistics, and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Dermatology, Kaiser Permanente Medical Center, Los Angeles, California, USA. Supported by a grant from the National Institute of Allergy and Infectious Disease (1RC1AI086107-01). Dr. Harrold has a consulting role with the Consortium of Rheumatology Researchers of North America (CORRONA) and was supported by K23AR053856 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Herrinton has research contracts with Centocor, Genentech, and Proctor and Gamble; Dr. Asgari with Genentech; and Dr. Wu with Abbott Laboratories, Amgen, and Pfizer. Dr. Gelfand receives grants to the trustees of the University of Pennsylvania from Amgen, Abbott, and Genentech, and has consulting roles with Amgen, Abbott, Centocor, Pfizer, and Merck. Dr. Curtis receives consulting fees/honoraria and research support from Roche/Genentech, UCB/Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, and Abbott and receives salary support from the U.S. National Institutes of Health (AR053351) and Agency for Healthcare Research and Quality (R01 R01HS018517). L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic; C. Salman, BS, Division of Research, Kaiser Permanente Northern California; S. Shoor, MD, The Permanente Medical Group; J.R. Curtis, MD, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.M. Asgari, MD, MPH, Division of Research, Kaiser Permanente Northern California, and Department of Dermatology, University of California at San Francisco; J.M. Gelfand, MD, MSCE, Departments of Dermatology, Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania; J.J. Wu, MD, Department of Dermatology, Kaiser Permanente Medical Center; L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California. Address correspondence to Dr. L.R. Harrold, Department of Medicine, University of Massachusetts Medical School, Biotech 4, Suite 315, 377 Plantation Street, Worcester, MA 01605, USA. E-mail: Leslie.Harrold{at}umassmed.edu Accepted for publication March 4, 2013.
Lisa J. Herrinton
From the Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic, Worcester, Massachusetts; Division of Research, Kaiser Permanente Northern California, Oakland, California; The Permanente Medical Group, Santa Clara, California; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Dermatology, University of California at San Francisco, San Francisco, California; Departments of Dermatology, Biostatistics, and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Dermatology, Kaiser Permanente Medical Center, Los Angeles, California, USA. Supported by a grant from the National Institute of Allergy and Infectious Disease (1RC1AI086107-01). Dr. Harrold has a consulting role with the Consortium of Rheumatology Researchers of North America (CORRONA) and was supported by K23AR053856 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Herrinton has research contracts with Centocor, Genentech, and Proctor and Gamble; Dr. Asgari with Genentech; and Dr. Wu with Abbott Laboratories, Amgen, and Pfizer. Dr. Gelfand receives grants to the trustees of the University of Pennsylvania from Amgen, Abbott, and Genentech, and has consulting roles with Amgen, Abbott, Centocor, Pfizer, and Merck. Dr. Curtis receives consulting fees/honoraria and research support from Roche/Genentech, UCB/Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, and Abbott and receives salary support from the U.S. National Institutes of Health (AR053351) and Agency for Healthcare Research and Quality (R01 R01HS018517). L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School, Meyers Primary Care Institute and Fallon Clinic; C. Salman, BS, Division of Research, Kaiser Permanente Northern California; S. Shoor, MD, The Permanente Medical Group; J.R. Curtis, MD, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.M. Asgari, MD, MPH, Division of Research, Kaiser Permanente Northern California, and Department of Dermatology, University of California at San Francisco; J.M. Gelfand, MD, MSCE, Departments of Dermatology, Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania; J.J. Wu, MD, Department of Dermatology, Kaiser Permanente Medical Center; L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California. Address correspondence to Dr. L.R. Harrold, Department of Medicine, University of Massachusetts Medical School, Biotech 4, Suite 315, 377 Plantation Street, Worcester, MA 01605, USA. E-mail: Leslie.Harrold{at}umassmed.edu Accepted for publication March 4, 2013.
Abstract
Objective Few studies based in well-defined North American populations have examined the occurrence of juvenile idiopathic arthritis (JIA), and none has been based in an ethnically diverse population. We used computerized healthcare information from the Kaiser Permanente Northern California membership to validate JIA diagnoses and estimate the incidence and prevalence of the disease in this well-characterized population.
Methods We identified children aged ≤ 15 years with ≥ 1 relevant International Classification of Diseases, 9th edition, diagnosis code of 696.0, 714, or 720 in computerized clinical encounter data during 1996–2009. In a random sample, we then reviewed the medical records to confirm the diagnosis and diagnosis date and to identify the best-performing case-finding algorithms. Finally, we used the case-finding algorithms to estimate the incidence rate and point prevalence of JIA.
Results A diagnosis of JIA was confirmed in 69% of individuals with at least 1 relevant code. Forty-five percent were newly diagnosed during the study period. The age- and sex-standardized incidence rate of JIA per 100,000 person-years was 11.9 (95% CI 10.9–12.9). It was 16.4 (95% CI 14.6–18.1) in girls and 7.7 (95% CI 6.5–8.9) in boys. The peak incidence rate occurred in children aged 11–15 years. The prevalence of JIA per 100,000 persons was 44.7 (95% CI 39.1–50.2) on December 31, 2009.
Conclusion The incidence rate of JIA observed in the Kaiser Permanente population, 1996–2009, was similar to that reported in Rochester, Minnesota, USA, but 2 to 3 times higher than Canadian estimates.
In this issue
The Journal of Rheumatology
Vol. 53, Issue 9
1 Sep 2026
Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996-2009
Leslie R. Harrold, Craig Salman, Stanford Shoor, Jeffrey R. Curtis, Maryam M. Asgari, Joel M. Gelfand, Jashin J. Wu, Lisa J. Herrinton
The Journal of Rheumatology Apr 2013, jrheum.120661; DOI: 10.3899/jrheum.120661
Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996-2009
Leslie R. Harrold, Craig Salman, Stanford Shoor, Jeffrey R. Curtis, Maryam M. Asgari, Joel M. Gelfand, Jashin J. Wu, Lisa J. Herrinton
The Journal of Rheumatology Apr 2013, jrheum.120661; DOI: 10.3899/jrheum.120661
